{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:48Z","timestamp":1793060028339,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T00:00:00Z","timestamp":1654992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The incidence of hepatitis E continues to increase and in immunocompromised patients can lead to chronic infection. Management of hepatitis E has evolved over time, with the first step being a reduction of immunosuppression followed by treatment with ribavirin. The European Association for the Study of Liver guidelines support treatment with ribavirin although the optimum dose and regime is unknown. This series reviews eight chronically infected cases treated between 2018 and 2021 in two UK centres (Ipswich Hospital and Addenbrooke's Hospital). Treatment response was defined primarily as sustained virological response at 12\u2009weeks (SVR12) following the cessation of treatment and secondly as sustained virological response at 24\u2009weeks (SVR24). The median dose of ribavirin given daily was 600\u2009mg. The management of five of the eight cases was in line with the guidelines, and treatment was stopped after 12\u2009weeks. Two of these five patients achieved SVR (40%). The remaining three cases were given a 24\u2010week course based on clinical judgement, and all achieved SVR (100%). The three patients who relapsed received a second 24\u2010week course of treatment and achieved SVR. Therefore, with a 24\u2010week course, a 100% treatment success rate was attained. In chronic hepatitis E, a 24\u2010week course of ribavirin would achieve optimum clearance rates with a single course of treatment. Ensuring the highest dose of ribavirin as possible (aiming to reach 800\u2009mg daily) and attempts to reduce immunosuppressive therapy safely may also be relevant to achieving SVR.<\/jats:p>","DOI":"10.1111\/jvh.13714","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T09:03:28Z","timestamp":1654160608000},"page":"817-822","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis E case series: A UK experience"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-5060","authenticated-orcid":false,"given":"Anne","family":"Robins","sequence":"first","affiliation":[{"name":"East Suffolk and North Essex NHS Foundation Trust  Ipswich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Dolman","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Williams","sequence":"additional","affiliation":[{"name":"East Suffolk and North Essex NHS Foundation Trust  Ipswich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gelson","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Mohsen","sequence":"additional","affiliation":[{"name":"East Suffolk and North Essex NHS Foundation Trust  Ipswich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,12]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"PublicHealthEngland.Guidance. Hepatitis E: Symptoms Transmission Treatment and Prevention.https:\/\/www.gov.uk\/government\/publications\/hepatitis\u2010e\u2010symptoms\u2010transmission\u2010prevention\u2010treatment\/hepatitis\u2010e\u2010symptoms\u2010transmission\u2010treatment\u2010and\u2010prevention: GOV.UK;2020."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-024-0942-0_3"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-024-0942-0_6"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14109"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706992"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02286.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12799"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2012.10.008"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2012.11.027"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001585"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omy059"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001908"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.005"},{"issue":"12","key":"e_1_2_11_15_1","first-page":"111","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"20","author":"Kamar N","year":"2014","journal-title":"N Engl J Med"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz953"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13456"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13424"},{"issue":"5","key":"e_1_2_11_19_1","first-page":"386","article-title":"Ribavirin monotherapy for the treatment of chronic hepatitis E in an Immunosuppressed patient","volume":"113","author":"Torres K","year":"2021","journal-title":"Spanish J Gastroenterol"},{"key":"e_1_2_11_20_1","unstructured":"EasternLiverNetwork.Management of Hepatitis Ehttps:\/\/easternliver.files.wordpress.com\/2021\/03\/management\u2010of\u2010hepatitis\u2010e\u2010v\u20101.0.pdf2021[cited2022January]."}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13714","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T03:56:46Z","timestamp":1692763006000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,12]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/jvh.13714"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13714","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,12]]},"assertion":[{"value":"2022-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}